Similar articles for PMID: 27057630

Year	Number of Results
2000	1
2004	3
2006	4
2007	4
2008	7
2009	11
2010	7
2011	9
2012	8
2013	11
2014	5
2015	7
2016	12
2017	6
2018	6
2019	2
2020	5
2021	1
2022	2
2023	1
2024	0

1

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.

Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. Wei SJ, et al. Oncotarget. 2016 May 31;7(22):32232-46. doi: 10.18632/oncotarget.8572. Oncotarget. 2016. PMID: 27057630 Free PMC article.

2

Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.

Wei SJ, Joseph T, Chee S, Li L, Yurlova L, Zolghadr K, Brown C, Lane D, Verma C, Ghadessy F. Wei SJ, et al. PLoS One. 2013 Nov 20;8(11):e81068. doi: 10.1371/journal.pone.0081068. eCollection 2013. PLoS One. 2013. PMID: 24278380 Free PMC article.

3

Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK. Chang YS, et al. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54. doi: 10.1073/pnas.1303002110. Epub 2013 Aug 14. Proc Natl Acad Sci U S A. 2013. PMID: 23946421 Free PMC article.

4

Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.

Chee SM, Wongsantichon J, Soo Tng Q, Robinson R, Joseph TL, Verma C, Lane DP, Brown CJ, Ghadessy FJ. Chee SM, et al. PLoS One. 2014 Aug 12;9(8):e104914. doi: 10.1371/journal.pone.0104914. eCollection 2014. PLoS One. 2014. PMID: 25115702 Free PMC article.

5

Identification of a Structural Determinant for Selective Targeting of HDMX.

Ben-Nun Y, Seo HS, Harvey EP, Hauseman ZJ, Wales TE, Newman CE, Cathcart AM, Engen JR, Dhe-Paganon S, Walensky LD. Ben-Nun Y, et al. Structure. 2020 Jul 7;28(7):847-857.e5. doi: 10.1016/j.str.2020.04.011. Epub 2020 Apr 30. Structure. 2020. PMID: 32359398 Free PMC article.

6

Peptide activators of the p53 tumor suppressor.

Zhan C, Lu W. Zhan C, et al. Curr Pharm Des. 2011;17(6):603-9. doi: 10.2174/138161211795222577. Curr Pharm Des. 2011. PMID: 21391910 Review.

7

In vitro selection of mutant HDM2 resistant to Nutlin inhibition.

Wei SJ, Joseph T, Sim AY, Yurlova L, Zolghadr K, Lane D, Verma C, Ghadessy F. Wei SJ, et al. PLoS One. 2013 Apr 30;8(4):e62564. doi: 10.1371/journal.pone.0062564. Print 2013. PLoS One. 2013. PMID: 23653682 Free PMC article.

8

The role of p53 in cancer drug resistance and targeted chemotherapy.

Hientz K, Mohr A, Bhakta-Guha D, Efferth T. Hientz K, et al. Oncotarget. 2017 Jan 31;8(5):8921-8946. doi: 10.18632/oncotarget.13475. Oncotarget. 2017. PMID: 27888811 Free PMC article. Review.

9

Effect of linker on the binding free energy of stapled p53/HDM2 complex.

Im H, Ham S. Im H, et al. PLoS One. 2020 Apr 30;15(4):e0232613. doi: 10.1371/journal.pone.0232613. eCollection 2020. PLoS One. 2020. PMID: 32353067 Free PMC article.

10

hDM2 protein-binding peptides screened from stapled α-helical peptide phage display libraries with different types of staple linkers.

Anananuchatkul T, Tsutsumi H, Miki T, Mihara H. Anananuchatkul T, et al. Bioorg Med Chem Lett. 2020 Dec 1;30(23):127605. doi: 10.1016/j.bmcl.2020.127605. Epub 2020 Oct 7. Bioorg Med Chem Lett. 2020. PMID: 33038548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year